Neuraxpharm Pharmaceuticals S.L.

Clinical research includes multiple sclerosis with attention to oral disease-modifying therapy and gastrointestinal tolerability in healthy volunteers. The sponsor’s portfolio in this area reflects interest in dimethyl fumarate and related fumarate-based treatments.

• Multiple sclerosis
• Dimethyl fumarate
• Gastrointestinal tolerability
• Oral disease-modifying therapy

These studies focus on treatment-related tolerability and comparative assessment of oral therapies used in neurological disease.